MLN8237
Showing 1 - 25 of 47
Lung Cancer, Mesothelioma Trial in Houston (Alisertib)
Completed
- Lung Cancer
- Mesothelioma
-
Houston, TexasUniversity of Texas MD Anderson Cancer Center
Sep 23, 2022
Head and Neck Squamous Cell Carcinoma, Malignant Solid Tumor Trial in Houston (Alisertib, Pembrolizumab)
Recruiting
- Head and Neck Squamous Cell Carcinoma
- Malignant Solid Neoplasm
- Alisertib
- Pembrolizumab
-
Houston, TexasM D Anderson Cancer Center
Dec 31, 2022
Metastatic Breast Cancer, Solid Tumors Trial in Aurora (Alisertib, MLN0128)
Completed
- Metastatic Breast Cancer
- Solid Tumors
-
Aurora, ColoradoUniversity of Colorado Cancer Center
May 17, 2022
Recurrent Lung Non-Small Cell Carcinoma, Stage IIIB Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8 Trial in Houston
Active, not recruiting
- Recurrent Lung Non-Small Cell Carcinoma
- +4 more
- Alisertib
- +2 more
-
Houston, TexasM D Anderson Cancer Center
Jul 31, 2022
Lung Cancer Metastatic, EGFR Gene Mutation Trial in San Francisco (Osimertinib, Alisertib)
Recruiting
- Lung Cancer Metastatic
- EGFR Gene Mutation
-
San Francisco, CaliforniaUniversity of California, San Francisco
Aug 10, 2022
Acute Megakaryoblastic Leukemia, Myelofibrosis, Primary Myelofibrosis Trial in Miami, Chicago, Rochester (Alisertib, Laboratory
Active, not recruiting
- Acute Megakaryoblastic Leukemia
- +2 more
- Alisertib
- +2 more
-
Miami, Florida
- +2 more
May 4, 2021
Acute Myeloid Leukemia Trial in Boston (Alisertib, Cytarabine, Idarubicin)
Advanced Solid Tumors, Ovarian Cancer, Small Cell Lung Cancer Trial in Chiba, Shizuoka, Seoul (Alisertib, Paclitaxel)
Terminated
- Advanced Solid Tumors
- +2 more
-
Chiba, Japan
- +2 more
Jun 11, 2019
Advanced Malignancies Trial in Nashville (Alisertib)
Completed
- Advanced Malignancies
-
Nashville, TennesseeSarah Cannon Research Institute (SCRI)
Nov 29, 2018
Advanced and Metastatic Gastric or Gastroesophageal Adenocarcinoma Trial in Spain, United States (MLN1117, TAK-659, Alisertib)
Terminated
- Advanced and Metastatic Gastric or Gastroesophageal Adenocarcinoma
- MLN1117
- +4 more
-
Lake Success, New York
- +5 more
Aug 19, 2019
Advanced Solid Tumors Trial in Santa Monica (Alisertib)
Completed
- Advanced Solid Tumors
-
Santa Monica, CaliforniaPremiere Oncology, A Medical Corporation
Mar 8, 2019
Advanced Solid Tumors, Lymphomas Trial in Tiong Bahru (Alisertib)
Completed
- Advanced Solid Tumors
- Lymphomas
-
Tiong Bahru, SingaporeNational Cancer Centre
Nov 29, 2018
Bladder Cancer, Transitional Cell Carcinoma Trial in Milano (Alisertib, Paclitaxel, Placebo)
Completed
- Bladder Cancer
- Transitional Cell Carcinoma
- Alisertib
- +2 more
-
Milano, Mi, ItalyFondazione IRCCS Istituto Nazionale dei Tumori
Apr 9, 2019
Advanced Solid Tumors, Relapsed/Refractory Lymphoma Trial in United States (Alisertib, Itraconazole)
Completed
- Advanced Solid Tumors
- Relapsed/Refractory Lymphoma
-
Saint Louis, Missouri
- +3 more
Aug 16, 2019
Advanced Solid Tumors, Adenocarcinoma of the Prostate Trial in United States (Alisertib, Docetaxel)
Completed
- Advanced Solid Tumors
- Adenocarcinoma of the Prostate
-
Indianapolis, Indiana
- +3 more
Oct 4, 2018
Advanced Solid Tumors, Lymphoma Trial in Tacoma ([^14C]-alisertib, alisertib)
Completed
- Advanced Solid Tumors
- Lymphoma
-
Tacoma, WashingtonComprehensive Clinical Development
Feb 20, 2018
Head Neck Cancer Trial in Philadelphia (MLN8237, Cetuximab, Radiotherapy)
Completed
- Head and Neck Cancer
- MLN8237
- +2 more
-
Philadelphia, PennsylvaniaAbramson Cancer Center of the University of Pennsylvania
Aug 28, 2018
Advanced Solid Tumors, Relapsed/Refractory Lymphoma Trial in United States (Alisertib)
Completed
- Advanced Solid Tumors
- Relapsed/Refractory Lymphoma
-
Miami, Florida
- +6 more
Apr 9, 2018
Solid Tumors, Lymphoma Trial in United States (Alisertib, Esomeprazole, Rifampin)
Estrogen Receptor Positive, Progesterone Receptor Positive, Recurrent Breast Carcinoma Trial in Rochester (Alisertib,
Completed
- Estrogen Receptor Positive
- +5 more
- Alisertib
- +2 more
-
Rochester, MinnesotaMayo Clinic
Oct 2, 2018